Newsfiscal.ai
Merck Discontinues Development of Sutro Biopharma-Partnered IL-2 Agonist MK-1484
· Published
Article summary
Merck & Co. has terminated the development of MK-1484, an IL-2 agonist candidate partnered with Sutro Biopharma, as part of a routine pipeline prioritization.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…